MedTrace Logo

Phase 1 Study of 3D229 in Healthy Subjects

NCT04941313 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-06-22

No results posted yet for this study

Summary

This is a Phase 1 Study to Evaluate the Safety and tolerability of 3D-229 in health subjects

Conditions

  • Healthy Subject

Interventions

DRUG

3D229

3D229 is an investigational drug.

OTHER

Placebo

Matching placebo

Sponsors & Collaborators

  • 3D Medicines

    lead INDUSTRY

Principal Investigators

  • xueying ding · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-27
Primary Completion
2021-11-15
Completion
2022-02-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04941313 on ClinicalTrials.gov